Novartis Faces Investor Scrutiny Over M&A Strategy After Drug Trial Failures

Novartis shareholders are intensifying their examination of the company's acquisition strategy following two significant drug trial failures, including the del-desiran drug. These setbacks, which raised concerns about last year's $12 billion Avidity acquisition, have resulted in a nearly $30 billion reduction in Novartis's market value. Some investors are now advocating for changes to the board to enhance M&A oversight.